Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva started at neutral at UBS on pricing and legal concerns (NYSE:TEVA) | Seeking Alpha
Teva boosted as FDA delays generic Copaxone - Globes
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Teva Has Potential For 6% CAGR Ahead, UBS Says In Upgrade
As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites | Ctech
Teva Pharmaceuticals Archives - Drug Discovery and Development
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Brussels' Teva probe reveals dark side of patent protections | Financial Times
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva Pharmaceutical Industries Stock Jumps on a Rare Bullish View | Barron's
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Storbank blåstempler Kåre Schultz' plan for Teva: Aktien er »for billig til at ignorere«
Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
